Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : Berna Biotech AG (Switzerland)

Berna Biotech AG (Switzerland) MAJ Il y a 4 ans

A phase III open, randomised, controlled study to evaluate the safety and immunogenicity of a paediatric dose (0.25 ml) and the standard dose (0.5 ml) of Epaxal® with reference to comparator vaccine in healthy children and adolescents (12 months to 16 years of age inclusive), using a 0/6 month schedule Not provided at time of registration

Pays Chile
Organes Aucun
Spécialités Aucune

Essai clos aux inclusions

Plus d'informations